Literature DB >> 21325423

Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.

Jennifer A Schwartz1, Linda Buonocore, Amorsolo Suguitan, Meredith Hunter, Preston A Marx, Kanta Subbarao, John K Rose.   

Abstract

We analyzed the ability of a vaccine vector based on vesicular stomatitis virus (VSV) to induce a neutralizing antibody (NAb) response to avian influenza viruses (AIVs) in rhesus macaques. Animals vaccinated with vectors expressing either strain A/Hong Kong/156/1997 or strain A/Vietnam/1203/2004 H5 hemagglutinin (HA) were able to generate robust NAb responses. The ability of the vectors to induce NAbs against homologous and heterologous AIVs after a single dose was dependent upon the HA antigen incorporated into the VSV vaccine. The vectors expressing strain A/Vietnam/1203/2004 H5 HA were superior to those expressing strain A/Hong Kong/156/1997 HA at inducing cross-clade NAbs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325423      PMCID: PMC3126271          DOI: 10.1128/JVI.02491-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

Review 2.  Emerging respiratory viruses: challenges and vaccine strategies.

Authors:  Laura Gillim-Ross; Kanta Subbarao
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

7.  The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus.

Authors:  M J Schnell; L Buonocore; M A Whitt; J K Rose
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.

Authors:  L E Iverson; J K Rose
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

9.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.

Authors:  Sagar U Kapadia; John K Rose; Elaine Lamirande; Leatrice Vogel; Kanta Subbarao; Anjeanette Roberts
Journal:  Virology       Date:  2005-09-30       Impact factor: 3.616

10.  SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.

Authors:  Sagar U Kapadia; Ian D Simon; John K Rose
Journal:  Virology       Date:  2008-04-08       Impact factor: 3.616

View more
  21 in total

1.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

Review 2.  Viruses - from pathogens to vaccine carriers.

Authors:  Juliana C Small; Hildegund C J Ertl
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

3.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

4.  Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.

Authors:  Gyoung Nyoun Kim; Kunyu Wu; Jiho Patrick Hong; Zain Awamleh; C Yong Kang
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

Review 5.  The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.

Authors:  A Sally Davis; Jeffery K Taubenberger; Mike Bray
Journal:  Antiviral Res       Date:  2015-03-05       Impact factor: 5.970

6.  A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Authors:  Alex B Ryder; Linda Buonocore; Leatrice Vogel; Raffael Nachbagauer; Florian Krammer; John K Rose
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

7.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

8.  Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Authors:  Andrea Marzi; Flora Engelmann; Friederike Feldmann; Kristen Haberthur; W Lesley Shupert; Douglas Brining; Dana P Scott; Thomas W Geisbert; Yoshihiro Kawaoka; Michael G Katze; Heinz Feldmann; Ilhem Messaoudi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

Review 9.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

10.  Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.

Authors:  Flavio Lauretti; Anasuya Chattopadhyay; Rafael Freitas de Oliveira França; Luiza Castro-Jorge; John Rose; Benedito A L da Fonseca
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.